Medical Microinstruments announced it hit significant commercial milestones for its surgical robot across two continents. The company develops the Symani surgical robot system, which the FDA cleared in April. Symani provides advanced solutions for a range of open surgeries. That includes post-mastectomy breast cancer reconstruction, extremity reconstruction using free tissue transfer and lymphatic system repair.
Related: FDA clears Orthofix Fitbone transport and lengthening system
Medical Microinstruments’ tiny NanoWrist instruments help to access and suture small, delicate anatomies. That includes veins, arteries, nerves and lymphatic vessels as small as 0.3mm in diameter. It provides motion scaling and tremor reduction to allow precise micro-movements. The articulated wrist features seven degrees of freedom that match the human wrist, tremor filtration and motion scaling.
First, the company reached an exclusive distribution agreement with Gunze Medical in Japan. It signals a step toward commercializing Symani across the country, upon regulatory approval.
Second, Medical Microinstruments expanded its commercialization efforts in Europe by partnering with the Synektik Group. Synektik covers six countries across Eastern Europe as the company looks to expand Symani’s footprint in that geography.
Symani now has regulatory approvals in 35 countries worldwide. Following the April clearance in the U.S., it most recently secured approvals in Hong Kong, Malaysia, New Zealand and Taiwan.
“The demand for innovative, less invasive, highly precise surgical options is increasing around the world, particularly in Asia, where microsurgery and reconstructive surgery both have long histories,” said Mark Toland, CEO of MMI. “Our recent regulatory approvals in multiple countries, and growing relationships with distributors in key markets, have enabled us to accelerate our timeline for global expansion. Each new milestone represents another step toward expanding patient access to highly advanced microsurgical capabilities around the world.”
